Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== External links == What's in an Oil Drop? An Introduction to Fourier Transform Ion Cyclotron Resonance (FT-ICR) for Non-scientists National High Magnetic Field Laboratory Scottish Instrumentation Resource Centre for Advanced Mass Spectrometry Fourier-transform Ion Cyclotron Resonance (FT-ICR) FT-ICR Introduction University of Bristol
== Recovery == As operator of the warehouse property, Lineage Inc., is responsible for debris removal, including 85 million pounds of food debris, site cleanup, and public nuisance mitigation, including odor mitigation and pest control. On July 13 2026, after more than 40 complaints from locals, South Coast Air Quality Management District issued a formal citation to Lineage for failure to control foul odor. Several relief funds have been established to help recover from disruptions from the fire, including the CCF Impact Fund, activated by the California Community Foundation to provide immediate relief for residents affected by the fire. Donations will fund direct cash assistance through Angeleno Cards, food distribution, air purifiers, masks, water, and other emergency essentials delivered through vetted community partners; and the Boyle Heights Fire Relief Fund which provides emergency financial assistance to small businesses and street vendors impacted by the fire. The California Community Foundation has provided grants to more than 20 community organizations working with residents impacted by the Lineage fire.
September 20, 2010: United States The National Bureau of Economic Research state that the US left the recession in June 2009, with managing director Lakshman Achuthan of the Economic Cycle Research Institute saying GDP recovered to 70% of the pre-recession level.
Sources: en.wikipedia.org
"Impact of elevated CO2 on shellfish calcification". Geophysical Research Letters. 34 (7): L07603. Bibcode:2007GeoRL..34.7603G. doi:10.1029/2006GL028554. hdl:20.500.11755/a8941c6a-6d0b-43d5-ba0d-157a7aa05668. Gattuso, J.-P.; Hansson, L.; "Ocean acidification" (Oxford University Press) Kroeker, K.; Kordas, R.; Crim, R.; Hendriks, I.; Ramajo, L.; Singh, G.; Duarte, C.; Gattuso, J.-P. (2013). "Impacts of ocean acidification on marine organisms: quantifying sensitivities and interaction with warming". Global Change Biology. 19 (6): 1884–1896. Bibcode:2013GCBio..19.1884K. doi:10.1111/gcb.12179. PMC 3664023. PMID 23505245. Gattuso, J.-P.; Magnan, A.; Billé, R.; Cheung, W.W.L.; Howes, E.L.; Joos, F.; Allemand, D.; Bopp, L.; Cooley, S.; Eakin, C.M.; Hoegh-Guldberg, O.; Kelly, R.P.; Pörtner, H.; Rogers, A.D.; Baxte, J.M.; Laffoley, D.; Osborn, D.; Rankovic, A.; Rochette, J.; Sumaila, U. R.; Treyer, S.; Turley, C. (2015). "Contrasting futures for ocean and society from different anthropogenic CO2 emissions scenarios" (PDF). Science. 349 (6243) aac4722. doi:10.1126/science.aac4722. PMID 26138982. S2CID 206639157. Magnan, A.K.; Colombier, M.; Billé, R.; Hoegh-Guldberg, O.; Joos, F.; Pörtner, H.-O; Waisman, H.; Spencer, T.; Gattuso, J.-P. (2016). "Implications of the Paris Agreement for the ocean". Nature Climate Change. 6 (8): 732–735. Bibcode:2016NatCC...6..732M. doi:10.1038/nclimate3038. Gattuso, J.-P.; Williamson, P.; Duarte, C.; Magnan, A.K. (2021). "The potential for ocean-based climate action: negative emissions technologies and beyond". Frontiers in Climate. 2 575716.
== Sources == L. S. Ettre (2004) American Laboratory, May 2004, pages 4-6 In memoriam: Csaba Horváth A. Guttman (2000) American Laboratory, June 2000, pages 6-10 Archived 2022-05-20 at the Wayback Machine Happy Birthday Csaba Horváth The Hungary Page Nobel Prize Winners and Famous Hungarians: Science, Mathematics & Technology Yale news of his death at the Wayback Machine (archived June 17, 2004) "Speeches at his remembrance Service". Archived from the original on June 18, 2004. Retrieved September 13, 2007. Claudia Flavell-White The Chemical Engineer October 2010 pp 54–55 "Degrees of Separation: Chemical Engineers who Changed the World - Csaba Horváth" An Introduction to Separation Science, (1973) B.L. Karger, Cs. Horváth and L.R. Snyder, Wiley
== Classification == The MEROPS protease classification system counts 14 superfamilies plus several currently unassigned families (as of 2013) each containing many families. Each superfamily uses the catalytic triad or dyad in a different protein fold and so represent convergent evolution of the catalytic mechanism. For superfamilies, P indicates a superfamily containing a mixture of nucleophile class families, and C indicates purely cysteine proteases. Within each superfamily, families are designated by their catalytic nucleophile (C denoting cysteine proteases).
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.